At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
AA4500 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind Study to Evaluate the Safety and Efficacy of Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Lipoma
In Brief
A Phase 2 clinical trial evaluating AA4500 and placebo for Lipoma. Completed, enrolled 19 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether collagenase is effective in reducing the surface area of a subcutaneous benign lipoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLipoma
CountriesUnited States
CollaboratorsAdvance Biofactures Corporation
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedSep 2014
Primary CompletionApr 2016
Study CompletionJun 2016
TodayJul 2026
First PostedSep 25, 2014
Enrollment StartAug 1, 2014
Primary CompletionApr 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.8 years ago
Interventions
AA4500drug
Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
placebodrug
Placebo